Clinical Implications of the Change in Glomerular Filtration Rate with Adrenergic Blockers in Patients with Morning Hypertension: The Japan Morning Surge-1 Study

Table 5

Change in eGFR, UACR and morning SBP at each CKD stage.

CKD stage	Change in eGFR (6th month minus baseline)		Change in UACR (6th month minus baseline)		Change in morning SBP (6th month minus baseline)
	Added treatment group (𝑛=308)	Control group (𝑛=303)	Added treatment group (𝑛=308)	Control group (𝑛=303)	Added treatment group (𝑛=308)	Control group (𝑛=303)
Stage 1	−6.4±15.5	−2.0±9.8	−4.3 (−16.9, 0.0)	−0.05 (−6.7, 4.4)	−14±14	−5.3±12
Stage 2	−2.5±7.5	−0.4±7.9	−3.2 (−20.8, 0.0)	0 (−7.3, 8.5)	−12±14	−3.2±15
Stage 3 + stage 4	−2.0±4.3	−1.5±5.8	0 (−27.0, 1.1)	0 (−19.2, 13.9)	−12±12	−5.5±13
𝑃 value	0.002	0.13	0.22	0.36	0.55	0.39

Changes in eGFR are shown as the means ± SD. Changes in UACR are expressed as the median values (25% value, 75% value). eGFR: estimated glomerular filtration rate; UACR: urinary albumin/creatinine ratio; CKD: chronic kidney disease; SBP: systolic blood pressure.
The numbers of patients per CKD stage are 111, 166, and 31 for CKD stages 1, 2, and 3 + 4 in the added treatment group and 104, 172, and 26 for these stages in the control group, respectively. The 𝑃 values were calculated by the Kruskal Wallis test for the change in eGFR and UACR and one-way analysis of variance for the change in morning SBP.